Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Circulation ; 130(9): 776-85, 2014 Aug 26.
Artículo en Inglés | MEDLINE | ID: mdl-24963038

RESUMEN

BACKGROUND: Pulmonary arterial hypertension is a chronic lung disease associated with severe pulmonary vascular changes. A pathogenic role of oxidized lipids such as hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids is well established in vascular disease. Apolipoprotein A-I mimetic peptides, including 4F, have been reported to reduce levels of these oxidized lipids and improve vascular disease. However, the role of oxidized lipids in the progression of pulmonary arterial hypertension and the therapeutic action of 4F in pulmonary arterial hypertension are not well established. METHODS AND RESULTS: We studied 2 different rodent models of pulmonary hypertension (PH): a monocrotaline rat model and a hypoxia mouse model. Plasma levels of hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids were significantly elevated in PH. 4F treatment reduced these levels and rescued preexisting PH in both models. MicroRNA analysis revealed that microRNA-193-3p (miR193) was significantly downregulated in the lung tissue and serum from both patients with pulmonary arterial hypertension and rodents with PH. In vivo miR193 overexpression in the lungs rescued preexisting PH and resulted in downregulation of lipoxygenases and insulin-like growth factor-1 receptor. 4F restored PH-induced miR193 expression via transcription factor retinoid X receptor α. CONCLUSIONS: These studies establish the importance of microRNAs as downstream effectors of an apolipoprotein A-I mimetic peptide in the rescue of PH and suggest that treatment with apolipoprotein A-I mimetic peptides or miR193 may have therapeutic value.


Asunto(s)
Hipertensión Pulmonar/tratamiento farmacológico , MicroARNs/fisiología , Péptidos/uso terapéutico , Animales , Proliferación Celular , Células Cultivadas , Humanos , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Hipertensión Pulmonar/etiología , Masculino , Ratones , Ratones Endogámicos C57BL , Músculo Liso Vascular/citología , Músculo Liso Vascular/metabolismo , Ratas , Ratas Sprague-Dawley , Receptor IGF Tipo 1/genética , Receptor alfa X Retinoide/fisiología
2.
Cancer ; 121 Suppl 17: 3130-45, 2015 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-26331820

RESUMEN

BACKGROUND: Previous studies have shown that the levels of 15-lipoxygenase 1 (15-LOX-1) and 15-LOX-2 as well as their metabolites 13-S-hydroxyoctadecadienoic acid (13(S)-HODE) and 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) are significantly reduced in smokers with non-small cell lung carcinoma (NSCLC). Furthermore, animal model experiments have indicated that the reduction of these molecules occurs before the establishment of cigarette smoking carcinogen-induced lung tumors, and this suggests roles in lung tumorigenesis. However, the functions of these molecules remain unknown in NSCLC. METHODS: NSCLC cells were treated with exogenous 13(S)-HODE and 15(S)-HETE, and then the ways in which they affected cell function were examined. 15-LOX-1 and 15-LOX-2 were also overexpressed in tumor cells to restore these 2 enzymes to generate endogenous 13(S)-HODE and 15(S)-HETE before cell function was assessed. RESULTS: The application of exogenous 13(S)-HODE and 15(S)-HETE significantly enhanced the activity of peroxisome proliferator-activated receptor γ (PPARγ), inhibited cell proliferation, induced apoptosis, and activated caspases 9 and 3. The overexpression of 15-LOX-1 and 15-LOX-2 obviously promoted the endogenous levels of 13(S)-HODE and 15(S)-HETE, which were demonstrated to be more effective in the inhibition of NSCLC. CONCLUSIONS: This study has demonstrated that exogenous or endogenous 13(S)-HODE and 15(S)-HETE can functionally inhibit NSCLC, likely by activating PPARγ. The restoration of 15-LOX activity to increase the production of endogenous 15(S)-HETE and 13(S)-HODE may offer a novel research direction for molecular targeting treatment of smoking-related NSCLC. This strategy can potentially avoid side effects associated with the application of synthetic PPARγ ligands.


Asunto(s)
Araquidonato 15-Lipooxigenasa/biosíntesis , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Ácidos Grasos Insaturados/administración & dosificación , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Antineoplásicos/administración & dosificación , Apoptosis/efectos de los fármacos , Araquidonato 15-Lipooxigenasa/genética , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/patología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , PPAR gamma/genética
3.
Artículo en Inglés | MEDLINE | ID: mdl-23500064

RESUMEN

Previous studies have indicated that 20-hydroxyeicosatetraeonic acid (20-HETE) modulates vascular tone in large cerebral and renal arteries through inhibition of the large conductance, calcium sensitive potassium (BK) channel activity. However, the role of 20-HETE in modulating tubuloglomerular feedback (TGF) and the myogenic response in the afferent arteriole (Af-Art) is unknown. The present study examined the effects of inhibitors of the synthesis and action of 20-HETE on the myogenic and TGF responses of isolated rabbit and mouse Af-Arts. Luminal diameter decreased by 9.2±0.5% in mice and 8.9±1.3% in rabbit Af-Art when the perfusion pressure was increased from 60 to 120 mmHg. Administration of a 20-HETE synthesis inhibitor, HET0016 (1 µM), or a selective 20-HETE antagonist, 6, 15-20-hydroxyeicosadienoic acid (6, 15-20-HEDE, 10 µM) completely blocked the myogenic response of both rabbit and mouse Af-Art, while addition of 5, 14-20-HEDE (10 µM), a 20-HETE agonist, restored the myogenic response in vessels treated with HET0016. Increases in NaCl concentration from 10 to 80 mM of the solution perfusing the macula densa constricted the Af-Art of rabbits by 6.0±1.4 µm (n=5). Addition of a 20-HETE agonist to the tubular perfusate potentiated the TGF-mediated vasoconstrictor response. This response was blocked by addition of a 20-HETE antagonist (6, 15-20-HEDE, 10 µM) to the vascular perfusate. These studies indicate that locally produced 20-HETE plays an important role in modulating the myogenic and TGF responsiveness of the Af-Art and may help explain how deficiencies in the renal formation of 20-HETE could promote the development of hypertension induced glomerular injury.


Asunto(s)
Arteriolas/efectos de los fármacos , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Hipertensión/fisiopatología , Aparato Yuxtaglomerular/efectos de los fármacos , Túbulos Renales/irrigación sanguínea , Animales , Ácido Araquidónico/administración & dosificación , Ácido Araquidónico/metabolismo , Arteriolas/fisiología , Presión Sanguínea/efectos de los fármacos , Humanos , Hipertensión/tratamiento farmacológico , Aparato Yuxtaglomerular/irrigación sanguínea , Glomérulos Renales/irrigación sanguínea , Glomérulos Renales/efectos de los fármacos , Túbulos Renales/efectos de los fármacos , Ratones , Microvasos/metabolismo , Microvasos/patología , Perfusión , Conejos
4.
Prostaglandins Other Lipid Mediat ; 102-103: 31-41, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23454652

RESUMEN

We have previously demonstrated that a stable synthetic analog of 20-HETE, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine (5,14-HEDGE), restores vascular reactivity, blood pressure, and heart rate in endotoxemic rats. The aim of this study was to determine whether decreased renal expression and activity of soluble epoxide hydrolase (sEH), MEK1, ERK1/2, IKKß, IκB-α, and NF-κB as well as systemic and renal proinflammatory cytokine production associated with increased expression and activity of CYP2C23 contributes to the effect of 5,14-HEDGE to prevent hypotension, tachycardia, inflammation, and mortality in response to systemic administration of lipopolysaccharide (LPS). Blood pressure fell by 33 mmHg and heart rate rose by 57 beats/min in LPS (10 mg/kg, i.p.)-treated rats. Administration of LPS also increased mRNA and protein expression of sEH associated with a decrease in CYP2C23 mRNA and protein expression. Increased activity of sEH and p-MEK1, p-ERK1/2, p-IκB-α, NF-κB, and p-NF-κB protein levels as well as TNF-α and IL-8 production by LPS were also associated with a decreased activity of AA epoxygenases. These effects of LPS were prevented by 5,14-HEDGE (30 mg/kg, s.c.; 1 h after LPS). Treatment of endotoxemic mice with 5,14-HEDGE also raised the survival rate of animals from 84% to 98%. A competitive antagonist of vasoconstrictor effects of 20-HETE, 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid, 20-HEDE (30 mg/kg, s.c.; 1 h after LPS) prevented the effects of 5,14-HEDGE on blood pressure, heart rate, expression and/or activity of sEH, CYP2C23, and ERK1/2 as well as TNF-α and IL-8 levels in rats treated with LPS. These results suggest that decreased expression and/or activity of sEH and MEK1/ERK1/2/IKKß/IκB-α/NF-κB pathway as well as proinflammatory cytokine production associated with increased CYP2C23 expression and antiinflammatory mediator formation participate in the protective effect of 5,14-HEDGE against hypotension, tachycardia, inflammation, and mortality in the rodent model of septic shock.


Asunto(s)
Sistema Enzimático del Citocromo P-450/biosíntesis , Epóxido Hidrolasas/biosíntesis , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Inflamación/tratamiento farmacológico , Lipopéptidos/administración & dosificación , Choque Séptico/tratamiento farmacológico , Animales , Presión Sanguínea/efectos de los fármacos , Citocromo P-450 CYP2J2 , Modelos Animales de Enfermedad , Regulación de la Expresión Génica/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Ácidos Hidroxieicosatetraenoicos/síntesis química , Hipotensión/tratamiento farmacológico , Hipotensión/patología , Inflamación/metabolismo , Inflamación/patología , Lipopéptidos/síntesis química , Sistema de Señalización de MAP Quinasas , Ratones , FN-kappa B/metabolismo , Ratas , Choque Séptico/metabolismo , Choque Séptico/patología , Sobrevida
5.
J Neurochem ; 121(1): 168-79, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22251169

RESUMEN

20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 metabolite of arachidonic acid that that contributes to infarct size following focal cerebral ischemia. However, little is known about the role of 20-HETE in global cerebral ischemia or neonatal hypoxia-ischemia (H-I). The present study examined the effects of blockade of the synthesis of 20-HETE with N-hydroxy-N'-(4-n-butyl-2-methylphenyl) formamidine (HET0016) in neonatal piglets after H-I to determine if it protects highly vulnerable striatal neurons. Administration of HET0016 after H-I improved early neurological recovery and protected neurons in putamen after 4 days of recovery. HET0016 had no significant effect on cerebral blood flow. cytochrome P450 4A immunoreactivity was detected in putamen neurons, and direct infusion of 20-HETE in the putamen increased phosphorylation of Na(+), K(+) -ATPase and NMDA receptor NR1 subunit selectively at protein kinase C-sensitive sites but not at protein kinase A-sensitive sites. HET0016 selectively inhibited the H-I induced phosphorylation at these same sites at 3 h of recovery and improved Na(+), K(+) -ATPase activity. At 3 h, HET0016 also suppressed H-I induced extracellular signal-regulated kinase 1/2 activation and protein markers of nitrosative and oxidative stress. Thus, 20-HETE can exert direct effects on key proteins involved in neuronal excitotoxicity in vivo and contributes to neurodegeneration after global cerebral ischemia in immature brain.


Asunto(s)
Amidinas/administración & dosificación , Isquemia Encefálica/metabolismo , Isquemia Encefálica/prevención & control , Ácidos Hidroxieicosatetraenoicos/antagonistas & inhibidores , Ácidos Hidroxieicosatetraenoicos/biosíntesis , Animales , Animales Recién Nacidos , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Infusiones Intraventriculares , Masculino , Porcinos
6.
J Exp Med ; 196(9): 1253-62, 2002 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-12417634

RESUMEN

The production of interleukin (IL)-12 is critical for the development of interferon (IFN)-gamma-dependent resistance to Toxoplasma gondii. Nevertheless, when this response is dysregulated, such as occurs in the absence of IL-10, the uncontrolled inflammation that results can have lethal consequences for the host. Recently, we demonstrated that lipoxin (LX)A(4), an eicosanoid mediator that depends on 5-lipoxygenase (LO) for its biosynthesis, exerts a regulatory role on dendritic cell IL-12 production triggered artificially by a T. gondii extract. We now formally establish the physiological relevance of this pathway in the systemic control of IL-12 production induced by live T. gondii infection and demonstrate its function to be distinct from that of IL-10. Thus, T. gondii-exposed wild-type, but not 5-LO-deficient animals, produced high levels of serum LXA(4) beginning at the onset of chronic infection. Moreover, 5-LO(-/-), in contrast to wild-type mice, succumbed during the same period displaying a marked encephalitis. The increased mortality of the 5-LO(-/-) animals was also associated with significant elevations of IL-12 and IFN-gamma and was completely prevented by the administration of a stable LXA(4) analogue. Together, these findings demonstrate a new pathway involving the induction of host LXs for the in vivo regulation of proinflammatory responses during microbial infection.


Asunto(s)
Araquidonato 5-Lipooxigenasa/inmunología , Ácidos Hidroxieicosatetraenoicos/inmunología , Interleucina-12/biosíntesis , Lipoxinas , Toxoplasmosis/inmunología , Animales , Encéfalo/patología , Células Cultivadas , Susceptibilidad a Enfermedades/inmunología , Femenino , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Ácidos Hidroxieicosatetraenoicos/sangre , Interferón gamma/sangre , Interleucina-10/sangre , Interleucina-12/sangre , Interleucina-12/inmunología , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Macrófagos/parasitología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Toxoplasma/inmunología , Toxoplasmosis/mortalidad , Toxoplasmosis/patología , Factor de Necrosis Tumoral alfa/biosíntesis
7.
J Invest Dermatol ; 84(6): 537-41, 1985 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-3998504

RESUMEN

The responses to 12-HETE in normal human skin have been investigated by means of intradermal and topical administration in 15 subjects. Intradermal infusion of 12-HETE produced a neutrophil polymorphonuclear and mononuclear infiltrate in the dermis. Topical administration resulted in a dose-related erythematous response to 200 ng-50 micrograms. This was accompanied by a neutrophil and mononuclear dermal infiltrate at 6 and 24 h after application. In addition, collections of neutrophils were present in the epidermis in 4 of 10 subjects biopsied at 6 h and in all patients biopsied 24 h after topical application. Intradermal and topical application of 9-hydroxyoctadecadienoic acid (9-HODD), a chemically similar but chemokinetically inactive substance, did not produce neutrophil infiltration of the epidermis, nor did the chemical irritant nonanoic acid. The results suggest that the cellular infiltrates produced in vivo in humans by 12-HETE are due to its chemoattractant properties and are not the result of a nonspecific inflammatory response.


Asunto(s)
Ácidos Hidroxieicosatetraenoicos/farmacología , Piel/efectos de los fármacos , Ácido 12-Hidroxi-5,8,10,14-Eicosatetraenoico , Administración Tópica , Biopsia , Quimiotaxis , Humanos , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Inyecciones Intradérmicas , Recuento de Leucocitos , Neutrófilos , Piel/patología
8.
Hypertension ; 27(3 Pt 2): 781-5, 1996 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-8613240

RESUMEN

Renal production of 20-hydroxyeicosatetraenoic acid (20-HETE), a cytochrome P-450-dependent arachidonate metabolite, increases during development of hypertension in spontaneously hypertensive rats, and inhibition of its production prevents hypertension. Since 20-HETE is a potent vasoconstrictor, these findings suggest that 20-HETE may contribute to the development of hypertension by elevating renal vascular resistance. In this study we examined the direct action of 20-HETE on the afferent arteriole, a vascular segment crucial to the control of renal vascular resistance. Rabbit afferent arterioles were microperfused at 60 mm Hg in vitro, and 20-HETE was added to the lumen. Although 20-HETE (10(-10) to 10(-6) mol/L) had no effect on the diameter of non-treated afferent arterioles (n=6), it caused dose-dependent constriction when vascular tone was increased with norepinephrine (0.3 micromol/L); 20-HETE at 10(-6) mol/L decreased diameter by 43 +/- 4% (n=6, P < .001). This constriction was abolished by disrupting the endothelium (n=5). Moreover, pretreatment with the cyclooxygenase inhibitor indomethacin (50 micromol/L) or the thromboxane/endoperoxide receptor antagonist SQ29548 (1 micromol/L) significantly (P < .03) attenuated 20-HETE-induced constriction: 20-HETE at 10(-6) mol/L constricted norepinephrine-treated afferent arterioles by 28 +/- 3% (n=6) and 25 +/- 4% (n=5), respectively. These results demonstrate that an increase in afferent arteriolar tone is required for the vasoconstrictor action of 20-HETE, which is partly mediated by the endothelial cyclooxygenase pathway. THus, increased production of 20-HETE in the kidney and increase in afferent arteriolar tone, both of which often precede the development of hypertension, may synergistically contribute to the development of hypertension by elevating renal vascular resistance.


Asunto(s)
Arteriolas/fisiología , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Riñón/irrigación sanguínea , Resistencia Vascular/efectos de los fármacos , Animales , Ácido Araquidónico/fisiología , Hipertensión/etiología , Riñón/fisiología , Masculino , Conejos
9.
Invest Ophthalmol Vis Sci ; 31(3): 535-9, 1990 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-2318592

RESUMEN

12(R)-hydroxyeicosatetraenoic acid (12(R)HETE) is an endogenous corneal epithelial arachidonic acid metabolite formed by the cytochrome P450 system and a potent inhibitor of Na(+)-K(+)-ATPase activity. We studied the effect of topically applied 12(R)HETE, either derived endogenously from corneal epithelium or synthetically prepared, on the IOP of the rabbit eye and compared it to its stereoisomer 12(S)HETE. Topical application of 1 microgram of biologically derived 12(R)HETE to both eyes of rabbits resulted in a marked reduction in IOP: a reduction of 4-7 mmHg occurred within 30-120 min. The IOP reduction effect of a single application of 12(R)HETE was long-lasting (9 days), whereas no effect on IOP was found for the vehicle control. Using synthetic compound, we demonstrated that the effect of 12(R)HETE on IOP is dose-dependent. Single topical application of 1, 10, and 50 micrograms of 12(R)HETE caused a reduction in IOP of 4, 6, and 12 mmHg, respectively. The stereoisomer, 12(S)HETE, did not have any effect on IOP at doses up to 5 micrograms. The IOP reduction effect of 12(R)HETE was not associated with hyperemia, appearance of flare, miotic response, or increased protein concentration of the aqueous humor. This study was the first to demonstrate that an endogenous inhibitor of Na(+)-K(+)-ATPase generated by the corneal epithelium potently and specifically lowers IOP in rabbits. Further studies are needed to elucidate the mechanism by which 12(R)HETE lowers IOP.


Asunto(s)
Ácidos Hidroxieicosatetraenoicos/farmacología , Presión Intraocular/efectos de los fármacos , Ácido 12-Hidroxi-5,8,10,14-Eicosatetraenoico , Administración Tópica , Análisis de Varianza , Animales , Humor Acuoso/metabolismo , Bovinos , Córnea/análisis , Relación Dosis-Respuesta a Droga , Proteínas del Ojo/metabolismo , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Ácidos Hidroxieicosatetraenoicos/síntesis química , Ácidos Hidroxieicosatetraenoicos/aislamiento & purificación , Isomerismo , Conejos , Relación Estructura-Actividad
10.
Artículo en Inglés | MEDLINE | ID: mdl-10765974

RESUMEN

The present study was conducted to delineate whether a possible mechanism for 13-(S)-hydroxyoctadecadienoic acid (13-HODE) and 15-hydroxyeicosatrienoic acid (15-HETrE) reversal of experimentally-induced skin hyperproliferation in guinea pig is via the modulation of epidermal nuclear mitogen activator protein (AP-1), a nuclear transcription factor associated with tissue turnover. The data revealed that topical application of 13-HODE and/or 15-HETrE on the induced hyperproliferative skin reversed the hyperproliferation and up-regulated the suppressed AP-1 expression. A further analysis of the two major subunits of AP-1 (c-fos and c-jun) revealed a selective up-regulation of c-fos. These results underscore the modulatory role of lipoxygenase-derived hydroxy fatty acids on nuclear transcription factors and explains, at least in part, the antiproliferative effects of 13-HODE and 15-HETrE.


Asunto(s)
División Celular/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Ácidos Hidroxieicosatetraenoicos/farmacología , Ácidos Linoleicos/farmacología , Piel/citología , Factor de Transcripción AP-1/genética , Administración Tópica , Animales , Ácidos Docosahexaenoicos/farmacología , Sinergismo Farmacológico , Células Epidérmicas , Epidermis/química , Cobayas , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Cinética , Ácidos Linoleicos/administración & dosificación , Masculino , Proteínas Proto-Oncogénicas c-fos/análisis , Proteínas Proto-Oncogénicas c-jun/análisis , Piel/química
11.
Eur J Pharmacol ; 258(1-2): 33-7, 1994 Jun 02.
Artículo en Inglés | MEDLINE | ID: mdl-7925597

RESUMEN

The thyroid gland synthesizes 6-delta-iodolactone, a compound shown to inhibit goiter growth in vivo and cell proliferation in culture. The present studies were performed to characterize this effect further with the aim of exploring the possible therapeutic action of iodolactones. Prevention assay: rats were treated simultaneously with a goitrogen, methylmercaptoimidazole, and either 6-delta-iodo-lactone or 14-iodo-omega-lactone, a synthetic derivative, given either i.p. or p. o. Both compounds caused a significant decrease in thyroid weight irrespective of the route of administration, but oral administration was less effective. A dose-response relationship was observed, the minimal effective dose (i.p.) being 3 micrograms/day. Involution assay: goiter was first induced with methylmercaptoimidazole and then the iodolactones were injected. Both compounds caused a significant involution, which was dose-related. Acute (10 days) administration of the iodolactones did not produce significant changes in several serum parameters (total T3 and T4, cholesterol, total protein, urea and acetylcholinesterase). These results give further support to the potential therapeutic application of iodolactones.


Asunto(s)
Ácidos Araquidónicos/farmacología , Bocio/prevención & control , Ácidos Hidroxieicosatetraenoicos/farmacología , Glándula Tiroides/efectos de los fármacos , Administración Oral , Animales , Ácidos Araquidónicos/administración & dosificación , Células Cultivadas , Relación Dosis-Respuesta a Droga , Femenino , Bocio/tratamiento farmacológico , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Inyecciones Intraperitoneales , Metimazol/farmacología , Ratas , Ratas Wistar , Glándula Tiroides/citología
12.
Inflammation ; 19(2): 193-205, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7601505

RESUMEN

Leukotriene B4 (LTB4) and 12(R)-hydroxyeicosatetraenoic acid [12(R)-HETE] are proinflammatory products of arachidonic acid metabolism that have been implicated as mediators in a number of inflammatory diseases. When injected intradermally into the guinea pig. LTB4 and 12(R)-HETE elicit a dose-dependent migration (chemotaxis) of neutrophils (PMNs) into the injection sites as assessed by the presence of a neutrophil marker enzyme myeloperoxidase. SC-41930 (7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxyl]-3,4-dihy dro-8-propyl-2H - 1-benzopyran-2-carboxylic acid), a first-generation LTB4 receptor antagonist, inhibited the chemotactic actions of LTB4 when given orally with an ED50 value of 1.7 mg/kg. The second-generation LTB4 receptor antagonist, SC-53228 [(+)-(S)-7-(3-(2-(cyclopropylmethyl)-3-methoxy-4- [(methylamino)carbonyl]phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1- benzopyran-2-propanoic acid], inhibited LTB4-induced chemotaxis when given intragastrically with an ED50 value of 0.07 mg/kg. Furthermore, SC-53228 inhibited 12(R)-HETE-induced granulocyte chemotaxis with an oral ED50 value of 5.8 mg/kg. When dosed orally over a range of 0.03-100 mg/kg, SC-53228 gave Cmax plasma concentrations of 0.015-41.1 micrograms/ml. SC-53228 inhibited LTB4-primed membrane depolarization of human neutrophils with an IC50 value of 34 nM. As a potent LTB4 receptor antagonist, SC-53228 may well have application in the medical management of disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease, contact dermatitis, and psoriasis, in which LTB4 and/or 12(R)-HETE are implicated as inflammatory mediators.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Benzamidas/farmacología , Benzopiranos/farmacología , Quimiotaxis de Leucocito/efectos de los fármacos , Ácidos Hidroxieicosatetraenoicos/farmacología , Leucotrieno B4/farmacología , Receptores de Leucotrieno B4/antagonistas & inhibidores , Piel/efectos de los fármacos , Ácido 12-Hidroxi-5,8,10,14-Eicosatetraenoico , Administración Oral , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Benzamidas/administración & dosificación , Benzopiranos/administración & dosificación , Biomarcadores , Granulocitos/efectos de los fármacos , Cobayas , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Inyecciones Intradérmicas , Leucotrieno B4/administración & dosificación , Masculino , Potenciales de la Membrana/efectos de los fármacos , Neutrófilos/efectos de los fármacos , Neutrófilos/enzimología , Peroxidasa/análisis , Receptores de Leucotrieno B4/fisiología , Piel/inmunología , Piel/patología
19.
Am J Physiol Regul Integr Comp Physiol ; 292(6): R2400-5, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17303679

RESUMEN

Previous studies have indicated that 20-hydroxyeicosatetraenoic acid (20-HETE) inhibits Na+ transport in the medullary thick ascending loop of Henle (mTALH), but the mechanisms involved remain uncertain. The present study compared the effects of 20-HETE with those of ouabain and furosemide on intracellular Na+ concentration ([Na+]i), Na+ -K+ -ATPase activity, and 86Rb+ uptake, an index of Na+ transport, in mTALH isolated from rats. Ouabain (2 mM) increased, whereas furosemide (100 microM) decreased, [Na+]i in the mTALH of rats. Ouabain and furosemide inhibited 86Rb+ uptake by 91 and 30%, respectively. 20-HETE (1 microM) had a similar effect as ouabain and increased [Na+]i from 19 +/- 1 to 30 +/- 1 mM. 20-HETE reduced Na+ -K+ -ATPase activity by 30% and 86Rb+ uptake by 37%, but it had no effect on 86Rb+ uptake or [Na+]i in the mTALH of rats pretreated with ouabain. 20-HETE inhibited 86Rb+ uptake by 12% and increased [Na+]i by 19 mM in mTALH pretreated with furosemide. These findings indicate that 20-HETE secondarily inhibits Na+ transport in the mTALH of the rat, at least, in part by inhibiting the Na+ -K+ -ATPase activity and raising [Na+]i.


Asunto(s)
Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Asa de la Nefrona/metabolismo , ATPasa Intercambiadora de Sodio-Potasio/metabolismo , Animales , Transporte Biológico Activo/efectos de los fármacos , Transporte Biológico Activo/fisiología , Relación Dosis-Respuesta a Droga , Activación Enzimática/efectos de los fármacos , Asa de la Nefrona/efectos de los fármacos , Masculino , Ratas , Ratas Sprague-Dawley
20.
Am J Physiol Lung Cell Mol Physiol ; 293(4): L1037-44, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17660330

RESUMEN

Airway smooth muscle (ASM) metabolizes arachidonic acid (AA) through various enzymatic pathways, including cytochrome P-450 (CYP-450) omega-hydroxylase, which leads to the production of 20-hydroxyeicosatetraenoic acid (20-HETE). The goal of this study was to delineate the mode of action of 20-HETE in human ASM cells. Isometric tension measurements demonstrated that 20-HETE induced a concentration-dependent relaxant effect in ASM on bronchi precontracted with either methacholine or AA. Relaxing effects of 20-HETE on resting tone were prevented by 10 nM iberiotoxin (IbTx), a BK(Ca) channel inhibitor. Microelectrode measurements showed that exogenous additions of 20-HETE (0.1-10 microM) hyperpolarized the membrane potential of human ASM cells. This concentration-dependent electrophysiological effect induced by the eicosanoid was prevented by 10 nM IbTx. Complementary experiments, using the planar lipid bilayer reconstitution technique, demonstrated that 20-HETE activated reconstituted BK(Ca) channels at low free Ca(2+) concentrations. Together, these results indicate that 20-HETE-dependent activation of BK(Ca) channels is responsible for the hyperpolarization and controlled relaxation of ASM in human distal bronchi.


Asunto(s)
Bronquios/efectos de los fármacos , Bronquios/fisiología , Ácidos Hidroxieicosatetraenoicos/farmacología , Canales de Potasio de Gran Conductancia Activados por el Calcio/metabolismo , Bronquios/metabolismo , Inhibidores de la Ciclooxigenasa/farmacología , Relación Dosis-Respuesta a Droga , Electrofisiología , Humanos , Ácidos Hidroxieicosatetraenoicos/administración & dosificación , Ácidos Hidroxieicosatetraenoicos/biosíntesis , Técnicas In Vitro , Contracción Isométrica , Canales de Potasio de Gran Conductancia Activados por el Calcio/antagonistas & inhibidores , Membrana Dobles de Lípidos/metabolismo , Potenciales de la Membrana/efectos de los fármacos , Relajación Muscular , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Concentración Osmolar , Péptidos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA